| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NMT2 |
| Uniprot No | O60551 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-498aa |
| 氨基酸序列 | MAEDSESAAS QQSLELDDQD TCGIDGDNEE ETEHAKGSPG GYLGAKKKKK KQKRKKEKPN SGGTKSDSAS DSQEIKIQQP SKNPSVPMQK LQDIQRAMEL LSACQGPARN IDEAAKHRYQ FWDTQPVPKL DEVITSHGAI EPDKDNVRQE PYSLPQGFMW DTLDLSDAEV LKELYTLLNE NYVEDDDNMF RFDYSPEFLL WALRPPGWLL QWHCGVRVSS NKKLVGFISA IPANIRIYDS VKKMVEINFL CVHKKLRSKR VAPVLIREIT RRVNLEGIFQ AVYTAGVVLP KPIATCRYWH RSLNPRKLVE VKFSHLSRNM TLQRTMKLYR LPDVTKTSGL RPMEPKDIKS VRELINTYLK QFHLAPVMDE EEVAHWFLPR EHIIDTFVVE SPNGKLTDFL SFYTLPSTVM HHPAHKSLKA AYSFYNIHTE TPLLDLMSDA LILAKSKGFD VFNALDLMEN KTFLEKLKFG IGDGNLQYYL YNWRCPGTDS EKVGLVLQ |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NMT2重组蛋白的3篇假设性参考文献示例，基于典型研究主题的合理推测：
---
1. **标题**：*Expression and Biochemical Characterization of Recombinant Human N-Myristoyltransferase 2 (NMT2)*
**作者**：Duronio, R.J. et al.
**摘要**：报道了利用大肠杆菌系统成功表达并纯化重组人源NMT2蛋白，分析了其酶动力学特性，发现其底物选择性与NMT1存在差异，为研究亚型功能分化提供了依据。
2. **标题**：*NMT2 Overexpression in Colorectal Cancer: Role of Recombinant Protein in Functional Assays*
**作者**：Selvakumar, P. et al.
**摘要**：通过重组NMT2蛋白的体外实验，揭示了其在结直肠癌细胞中异常高表达对肿瘤增殖的促进作用，并验证了其作为潜在治疗靶点的可能性。
3. **标题**：*High-Throughput Screening of NMT2 Inhibitors Using a Fluorescence-Based Assay*
**作者**：Thinon, E. et al.
**摘要**：开发了基于重组NMT2蛋白的荧光检测方法，筛选出选择性小分子抑制剂，为抗寄生虫及抗癌药物研发提供了先导化合物。
---
**注**：以上文献为示例性质，实际研究中请通过PubMed、Web of Science等数据库检索真实发表的论文。
N-Myristoyltransferase 2 (NMT2) is a member of the N-myristoyltransferase enzyme family that catalyzes the covalent attachment of myristate, a 14-carbon saturated fatty acid, to the N-terminal glycine of specific protein substrates. This post-translational modification, termed N-myristoylation, plays a critical role in regulating protein-membrane interactions, intracellular trafficking, and functional activation. While NMT1 (the isoform NMT1) is ubiquitously expressed, NMT2 exhibits tissue-specific expression patterns, with higher activity observed in the brain, heart, and certain cancer cells. Both isoforms share structural homology but differ in substrate preferences and regulatory mechanisms.
The development of recombinant NMT2 protein has been driven by its emerging role in disease pathogenesis. NMT2 dysregulation has been implicated in cancer progression through the aberrant myristoylation of oncoproteins like Src-family kinases. It also contributes to viral replication by modifying viral capsid proteins in pathogens such as HIV and hepatitis B virus. Additionally, NMT2-mediated myristoylation is critical for neuronal signaling proteins, linking it to neurodegenerative disorders. Recombinant NMT2 enables researchers to study substrate specificity, screen inhibitors, and characterize structural dynamics through X-ray crystallography and biochemical assays.
Produced typically in Escherichia coli or mammalian expression systems, recombinant NMT2 retains catalytic activity when purified via affinity chromatography. Its applications span from deciphering disease mechanisms to high-throughput drug discovery, particularly for isoform-specific inhibitors. Recent studies highlight NMT2's potential as a therapeutic target, with its recombinant form serving as a vital tool for validating drug candidates and understanding myristoylation's broader biological implications in cell signaling and disease biology.
×
